The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single dose of mRNA-1345 vaccine in the prevention of a first episode of RSV-associated lower respiratory tract disease (RSV-LRTD) as compared with placebo from 14 days postinjection through 12 months. The main purpose of Part B of this study is to evaluate the safety, tolerability and immunogenicity of a booster dose (BD) of mRNA-1345 administered 24 months after the primary dose.
The study will be conducted in 2 phases: Phase 2 and Phase 3. In the Part A Phase 2 segment, up to 2,000 participants will be randomly assigned to receive a single injection of either mRNA-1345 vaccine at the selected dose or placebo in a 1:1 randomization ratio. In the Part A Phase 3 segment, approximately 35,000 participants will be randomly assigned to receive a single injection of either mRNA-1345 vaccine at the selected dose or placebo in a 1:1 randomization ratio. In the Part B substudy, 1500 participants who received a dose of mRNA-1345 in Part A Phase 3 will be randomly assigned in a 2:1 randomization ratio to receive a single BD injection of either mRNA-1345 at the selected dose or placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
36,814
AES - DRS - Synexus Clinical Research US, Inc. - Birmingham
Birmingham, Alabama, United States
Accel Research Site - Achieve - Birmingham
Birmingham, Alabama, United States
Lakeview Clinical Research
Guntersville, Alabama, United States
AES - DRS - Optimal Research Alabama - Huntsville
Huntsville, Alabama, United States
Hope Research Institute LLC - Hunt - PPDS
Hunt, Arizona, United States
Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)
Time frame: Up to 7 days after each injection
Number of Participants with Unsolicited Adverse Events (AEs)
Time frame: Up to 28 days after each injection
Number of Participants With Medically Attended AEs (MAAEs), Adverse Events of Special Interests (AESIs), Serious Adverse Events (SAEs), and AEs Leading to Withdrawal
Time frame: Up to BD Day 181
Vaccine Efficacy (VE) of mRNA-1345 to Prevent a First Episode of RSV-LRTD with 2 or More Symptoms
VE of mRNA-1345 to prevent reverse transcription polymerase chain reaction (RT-PCR) confirmed protocol-defined RSV-LRTD, defined as 100\*(1-HR ratio), where HR is the hazard ratio (mRNA-1345 versus placebo).
Time frame: From 14 days postinjection up to 12 months postinjection
VE of mRNA-1345 to Prevent a First Episode of RSV-LRTD with 3 or More Symptoms
VE of mRNA-1345 to prevent reverse transcription polymerase chain reaction (RT-PCR) confirmed protocol-defined RSV-LRTD, defined as 100\*(1-HR ratio), where HR is the hazard ratio (mRNA-1345 versus placebo).
Time frame: From 14 days postinjection up to 12 months postinjection
Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) and Respiratory Syncytial Virus Subtype B (RSV-B) Neutralizing Antibodies
Time frame: BD Day 29
Geometric Mean Ratio (GMR) of Serum RSV-A and RSV-B Neutralizing Antibodies After BD Compared to After Initial Dose
Time frame: BD Day 29
VE of mRNA-1345 to Prevent a First Episode of RSV-Associated Acute Respiratory Disease (RSV-ARD)
VE of mRNA-1345 to prevent RT-PCR confirmed protocol-defined RSV-ARD, defined as 100\*(1-HR ratio), where HR is the hazard ratio (mRNA-1345 versus placebo).
Time frame: From 14 days postinjection up to 12 months postinjection
VE of mRNA-1345 to Prevent First Hospitalization Associated with RSV-ARD or RSV-LRTD
VE of mRNA-1345 to prevent first hospitalization associated with RSV-ARD or RSV-LRTD, defined as 100\*(1-HR ratio), where HR is the hazard ratio (mRNA-1345 versus placebo).
Time frame: From 14 days postinjection up to 12 months postinjection
GMT of Serum RSV Neutralizing Antibodies
Time frame: Baseline through up to 24 months postinjection
Geometric Mean Concentration (GMC) of Serum RSV Binding Antibodies
Time frame: Baseline through up to 24 months postinjection
Seroresponse Rate in RSV Neutralizing Antibodies
Time frame: Baseline through up to 24 months postinjection
Geometric Mean Fold-Rise (GMFR) of Postbaseline/Baseline Antibody Titers
Time frame: Baseline through up to 24 months postinjection
Proportion of Participants with ≥4-fold Increases in Antibody Titers from Baseline
Time frame: Baseline through up to 24 months postinjection
Seroresponse Rate (SRR) Difference Between Serum RSV-A and RSV-B Neutralizing Antibodies After BD Compared to After Initial Dose
Time frame: BD Day 29
GMT of Serum RSV-A and RSV-B Neutralizing Antibodies
Time frame: BD Day 1 and Day 181
GMFR of Serum RSV-A and RSV-B Neutralizing Antibodies from Pre-primary Dose (Baseline)
Time frame: Baseline, BD Day 1, Day 29 and Day 181
SRR of Serum RSV-A and RSV-B Neutralizing Antibodies from Pre-primary Dose (Baseline)
Time frame: Baseline, BD Day 1, Day 29 and Day 181
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Hope Research Institute LLC - Hunt - PPDS
Hunt, Arizona, United States
Desert Clinical Research, LLC - CCT
Mesa, Arizona, United States
Hope Research Institute LLC - Phoenix - Hunt - PPDS
Phoenix, Arizona, United States
AES - DRS - Synexus Clinical Research US, Inc. - Phoenix Central
Phoenix, Arizona, United States
Synexus Clinical Research US, Inc. - Phoenix Southeast
Phoenix, Arizona, United States
...and 259 more locations